Patronus Biotech advances its malaria vaccine pipeline after receiving regulatory approval for a Phase I human trial in Australia targeting two primary malaria strains.
Patronus Biotech has achieved a significant regulatory milestone with the approval from the Bellberry Limited research ethics committee to initiate its first-in-human clinical trial in Australia. This Phase I study focuses on evaluating novel virus-like particle (VLP) based vaccine candidates designed to combat both Plasmodium falciparum and Plasmodium vivax malaria strains.
The trial is testing novel virus-like particle (VLP) based malaria vaccine candidates against Plasmodium falciparum and Plasmodium vivax.
The trials are approved to be conducted in Australia.
Patronus Biotech has received ethical clearance from Bellberry Limited to initiate its first human clinical trial in Australia. The study will evaluate novel virus-like particle (VLP) vaccine candidates designed to combat Plasmodium falciparum and Plasmodium vivax malaria strains.
The approval allows Patronus Biotech to transition its VLP-based malaria vaccine candidates into Phase I human clinical trials in Australia, marking a critical milestone in the drug development process.